Respiratory Infections

Latest News


Latest Videos


CME Content


More News

In 2018, the FDA approved omadacycline as a new oral/intravenous third generation tetracycline to treat Community Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Here is a clinical overview of omadacycline as well as recent phase 2 clinical trial results favoring oral omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease.

A new modeling analysis shows the potential increases in cases, hospitalizations, deaths, as well as the healthcare costs associated with declining vaccination rates. Patricia Stinchfield, RN, MS, CPNP, offers commentary on the evolving measles outbreaks, discusses the vulnerable populations that are more at risk for contracting severe measles, and strategies to increase vaccination.